3 Warren Buffett Stocks to Buy and 2 to Avoid
Few investors have run circles around the broader market quite like Warren Buffett, CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B). Even though Buffett hasn't exactly outperformed the broad-based S&P 500 over the past decade, his performance over the past 55 years speaks volumes. Whereas the S&P 500 has risen by a cool 19,784% since 1965, inclusive of dividends, Berkshire Hathaway's per-share market value has soared an almost unfathomable 2,744,062%.
Having averaged an
Berkshire Hathaway has a 46-security portfolio that, as of this past weekend, was worth about $211 billion. Many of these 46 securities are sound businesses that, over the long run, should generate wealth for shareholders.
But among these 46 holdings, three stand out as being particularly attractive investments at the moment, while two of Buffett's holdings are best avoided in their entirety.
Buy it: U.S. Bancorp
Easily one of the most attractive companies in Buffett's portfolio, and one he's been eagerly adding to recently, is U.S. Bancorp (NYSE: USB).
As of this past weekend, U.S. Bancorp was valued at 24% above its book value. For context, it hasn't ended a year at less than 66% above its book value in over a decade. The reason it commands such a premium relative to other big banks is the fact that it
Whereas most big banks were lured into risky derivatives prior to the financial crisis, U.S. Bancorp avoided this temptation. This left it uniquely positioned following the financial fallout to rebound much faster than its peers. When coupled with its efforts to
In other words, anytime U.S. Bancorp nears its book value, it becomes an attractive stock to buy.
Buy it: Teva Pharmaceutical Industries
Though it's not a stock that all investors will have the stomach to own, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE: TEVA) has all the makings of an undervalued company that can make investors some serious money.
Teva has been pressured in recent years by legal settlements, a burdensome debt load tied to its Actavis deal, the loss of exclusivity for its top-selling brand-name drug Copaxone, and more recently by its ties to the opioid crisis. Yet the company
On a longer-term basis, Teva stands to benefit from an aging global population that's gaining increased access to prescription medicines, as well as rising brand-name drug costs that'll only fuel demand for cheaper generics. In other words, Teva's pricing power should steadily improve over time. That's great news for a company
Buy it: Amazon
You might think e-commerce giant Amazon.com (NASDAQ: AMZN) is pricey at $2,500 a share, but that couldn't be further from the truth. In reality, Amazon might end the year at a cheaper valuation than at any point over the past decade.
One of my favorite metrics when analyzing the
Though Amazon's roughly 40% e-commerce market share and its more than 150 million worldwide Prime members are key selling points of this stock, the
Avoid it: Occidental Petroleum
One thing to know about picking stocks is that no one is perfect, even the great Warren Buffett.
Last year, Buffett handed over $10 billion to Occidental Petroleum (NYSE: OXY) to aid in its acquisition of Anadarko. In return, Buffett
The biggest issue for Occidental is the company's debt load, which stood at close to $42 billion at the end of the most recent quarter. The expectation had been that Occidental Petroleum would sell a number of noncore assets to immediately bring down its debt to more manageable levels. But with oil demand (and per-barrel prices) falling off a cliff, some of these deals haven't come to fruition. My Foolish colleague Matt DiLallo
Avoid it: Kraft Heinz
In all likelihood, if Buffett could have sold out of Kraft Heinz (NASDAQ: KHC) years ago, he probably would have. But with Berkshire Hathaway holding 325.6 million shares in Kraft Heinz, equating to 26.7% of all outstanding shares, selling its stake would be practically impossible to do without further crushing its share price.
Kraft Heinz's packaged foods actually
But a few months does not a trend make. Kraft Heinz ended its latest quarter with $35 billion in goodwill, $31.5 billion in long-term debt, and only $5.4 billion in cash and cash equivalents. It still needs to divest assets to bring its leverage down, and has very little capital that can be devoted to helping bolster its packaged food brands. While a rebound is possible, Kraft Heinz's balance sheet
10 stocks we like better than Amazon
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the
*Stock Advisor returns as of June 2, 2020
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.